These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 9422070)

  • 21. [Early phase II study of S-1 in patients with advanced head and neck cancer. S-1 Cooperative Study Group (Head and Neck Working Group)].
    Inuyama Y; Kida A; Tsukuda M; Kohno N; Satake B
    Gan To Kagaku Ryoho; 1998 Jul; 25(8):1151-8. PubMed ID: 9679577
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [A late phase II clinical study of S-1 in patients with progressed, refractory breast cancer].
    Saeki T; Takashima S; Sano M; Horikoshi N; Miura S; Shimizu S; Morimoto K; Kimura M; Taguchi T
    Gan To Kagaku Ryoho; 2004 Apr; 31(4):539-47. PubMed ID: 15114697
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase I pharmacokinetic study of S-1 plus cisplatin in patients with advanced gastric carcinoma.
    Ajani JA; Faust J; Ikeda K; Yao JC; Anbe H; Carr KL; Houghton M; Urrea P
    J Clin Oncol; 2005 Oct; 23(28):6957-65. PubMed ID: 16145066
    [TBL] [Abstract][Full Text] [Related]  

  • 24. S-1 plus cisplatin combination chemotherapy in patients with advanced non-small cell lung cancer: a multi-institutional phase II trial.
    Ichinose Y; Yoshimori K; Sakai H; Nakai Y; Sugiura T; Kawahara M; Niitani H
    Clin Cancer Res; 2004 Dec; 10(23):7860-4. PubMed ID: 15585618
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Two elderly patients with advanced gastric cancer responding to chronomodulation chemotherapy with tegafur + cisplatin + isovorin followed by oral administration of S-1].
    Kobayashi A; Yamaguchi M
    Gan To Kagaku Ryoho; 2001 Jul; 28(7):1003-7. PubMed ID: 11478129
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Combination therapy of continuous venous infusion (CVI) of 5-FU and low dose consecutive cisplatin (CDDP), and the new oral anti-cancer drug S-1 for advanced gastro-intestinal cancer].
    Shirasaka T; Aiba K; Araki H; Suzuki M; Terashima M; Mikami Y
    Gan To Kagaku Ryoho; 1999 Mar; 26(4):456-66. PubMed ID: 10097742
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [A trial of TS-1 administration on the basis of the pharmacokinetic study for an advanced gastric cancer patient with impaired renal function].
    Yamamoto K; Imamura H; Furukawa H; Kishimoto T; Tanaka J; Oshiro R; Tatsuta M; Masutani S; Fukunaga M; Nakayama T; Takemoto H; Kondo M; Kamigaki S; Kawasaki T
    Gan To Kagaku Ryoho; 2005 Oct; 32(11):1748-51. PubMed ID: 16315929
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [An early phase II clinical study of S-1 in patients with breast cancer. S-1 Cooperative Study Group (Breast Cancer Working Group)].
    Taguchi T; Morimoto K; Horikoshi N; Takashima S; Toge T; Kimura M; Sano M; Aoyama H; Ota J; Noguchi S
    Gan To Kagaku Ryoho; 1998 Jun; 25(7):1035-43. PubMed ID: 9644319
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A phase I study of combination therapy of the oral fluorinated pyrimidine compound S-1 with low-dose cisplatin twice-a-week administration (JFMC27-9902 Step2) in patients with advanced gastric cancer using a continual reassessment method.
    Morita S; Nakata B; Tsuji A; Mitachi Y; Shirasaka T; Saji S; Ohashi Y; Sakamoto J; Hirakawa K
    Jpn J Clin Oncol; 2007 Dec; 37(12):924-9. PubMed ID: 18211983
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Possible regulation of 5-fluorouracil-induced neuro- and oral toxicities by two biochemical modulators consisting of S-1, a new oral formulation of 5-fluorouracil.
    Kato T; Shimamoto Y; Uchida J; Ohshimo H; Abe M; Shirasaka T; Fukushima M
    Anticancer Res; 2001; 21(3B):1705-12. PubMed ID: 11497250
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Late phase II study of S-1 in patients with advanced head and neck cancer].
    Inuyama Y; Kida A; Tsukuda M; Kohno N; Satake B;
    Gan To Kagaku Ryoho; 2001 Oct; 28(10):1381-90. PubMed ID: 11681245
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of gastrectomy on the pharmacokinetics of 5-fluorouracil and gimeracil after oral administration of S-1.
    Tsuruoka Y; Kamano T; Kitajima M; Kawai K; Watabe S; Ochiai T; Sakamoto K; Shirasaka T
    Anticancer Drugs; 2006 Apr; 17(4):393-9. PubMed ID: 16549996
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Postoperative chemotherapy with a novel oral anticancer drug composed of tegafur, gimeracil and oteracil potassium to curability C scirrhus type gastric cancer].
    Iwatani Y; Shimada Y; Ohshima T; Kusunoki N; Yamazaki T; Miyazaki N
    Gan To Kagaku Ryoho; 2001 Aug; 28(8):1129-32. PubMed ID: 11525030
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Concentration of FT and CDHP and 5-FU in the ascites fluid of patient with peritoneal carcinomatosis after new anti-cancer drug TS-1 oral administration].
    Iizuka R; Takahashi S; Kakihara N; Matsumura H; Takenaka A
    Gan To Kagaku Ryoho; 2002 Jul; 29(7):1251-3. PubMed ID: 12146009
    [No Abstract]   [Full Text] [Related]  

  • 35. Phase II study of S-1, a novel oral fluorophyrimidine derivative, in patients with metastatic colorectal carcinoma. S-1 Cooperative Colorectal Carcinoma Study Group.
    Ohtsu A; Baba H; Sakata Y; Mitachi Y; Horikoshi N; Sugimachi K; Taguchi T
    Br J Cancer; 2000 Jul; 83(2):141-5. PubMed ID: 10901361
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetic evaluation of novel oral fluorouracil antitumor drug S-1 in Chinese cancer patients.
    Zhuang ZX; Zhu H; Wang J; Zhu MG; Wang H; Pu WY; Bian HH; Chen L; Zhang H
    Acta Pharmacol Sin; 2013 Apr; 34(4):570-80. PubMed ID: 23396375
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Potassium oxonate, an enzyme inhibitor compounded in S-1, reduces the suppression of antitumor immunity induced by 5-fluorouracil.
    Yamashita T; Ueda Y; Fuji N; Itoh T; Kurioka H; Shirasaka T; Yamagishi H
    Cancer Chemother Pharmacol; 2006 Aug; 58(2):183-8. PubMed ID: 16317557
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Clinical evaluation of S-1, a new anticancer agent, in patients with advanced gastrointestinal cancer. S-1 Cooperative Gastrointestinal Study Group].
    Maehara Y; Sugimachi K; Kurihara M; Taguchi T
    Gan To Kagaku Ryoho; 1999 Mar; 26(4):476-85. PubMed ID: 10097744
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase I study of the sequential administration of S-1 and cisplatin for metastatic gastric cancer.
    Baba E; Fujishima H; Kusaba H; Esaki T; Ariyama H; Kato K; Tanaka R; Mitsugi K; Shibata Y; Harada M; Nakano S
    Anticancer Res; 2009 May; 29(5):1727-32. PubMed ID: 19443394
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [TS-1 treatment for progressive gastric cancer in a patient on chronic dialysis--assessment of dosage regimen by monitoring blood concentrations of therapeutic drugs (TDM)].
    Tanaka T; Fujita S; Tanaka N; Ooka M; Okajima S; Tanaka N
    Gan To Kagaku Ryoho; 2005 Jun; 32(6):841-5. PubMed ID: 15984528
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.